GDF-15 and Early Outcomes After LVAD Implantation

NCT07497308 | Recruiting

• 1 other identifier: AKD-LVAD-GDF15-2026
• Study Type: observational
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

This observational study aims to investigate the association between preoperative GDF-15 levels and early postoperative outcomes in patients undergoing left ventricular assist device (LVAD) implantation. The study will evaluate whether elevated preoperative GDF-15 levels are associated with adverse early outcomes, including postoperative complications and mortality. The findings may help improve preoperative risk assessment and identify high-risk patients before LVAD implantation.

Conditions

Advanced Heart Failure; Left Ventricular Assist Device Implantation

Keywords

Left Ventricular Assist Device; GDF-15; Postoperative Outcomes; Early Mortality

Outcome Measures

Primary Outcomes (1)

• Early Postoperative Mortality

  Mortality occurring during the early postoperative period after LVAD implantation

  30 days after LVAD implantation

Secondary Outcomes (1)

• Postoperative Complications

  Up to 30 days after LVAD implantation

Study Arms (1)

Patients Undergoing LVAD Implantation

Patients with advanced heart failure undergoing left ventricular assist device (LVAD) implantation whose preoperative GDF-15 levels will be evaluated in relation to early postoperative outcomes and mortality.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of adult patients with advanced heart failure undergoing LVAD implantation. Eligible participants are those with available preoperative GDF-15 measurements who meet the study inclusion and exclusion criteria.

You may qualify if:

• Patients with advanced heart failure undergoing LVAD implantation
• Availability of preoperative GDF-15 measurement
• Ability to provide written informed consent or consent provided by a legally authorized representative, according to local regulations -

You may not qualify if:

• Active infection
• Active malignancy
• Severe hepatic failure
• Missing study data
• Refusal to participate

Sponsors & Collaborators

• Akdeniz University: lead

Study Sites (1)

Akdeniz University, Faculty of Medicine, Department of Anesthesiology and Reanimation

Antalya, Please Select:, 07050, Turkey (Türkiye)

RECRUITING

Central Study Contacts

emel gündüz, md

CONTACT

+902422496000; dregunduz@hotmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor of Anesthesiology, Akdeniz University, Antalya, Turkey

Study Record Dates

• First Submitted: March 19, 2026
• First Posted: March 27, 2026
• Study Start: February 4, 2026
• Primary Completion (Estimated): August 10, 2026
• Study Completion (Estimated): December 23, 2026
• Last Updated: March 27, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)